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ARTICLE OPEN
Polygenic risk score for the prediction of breast cancer
is related to lesser terminal duct lobular unit involution
of the breast
Clara Bodelon 1✉, Hannah Oh1,2, Andriy Derkach1, Joshua N. Sampson1, Brian L. Sprague3, Pamela Vacek3, Donald L. Weaver3,
Shaoqi Fan1, Maya Palakal1, Daphne Papathomas1, Jackie Xiang1, Deesha A. Patel1, Laura Linville1, Susan E. Clare 4,
Daniel W. Visscher5, Carolyn Mies6, Stephen M. Hewitt7, Louise A. Brinton1, Anna Maria V. Storniolo8, Chunyan He 9,10,
Stephen J. Chanock 1, Montserrat Garcia-Closas 1, Gretchen L. Gierach 1,12 and Jonine D. Figueroa 1,11,12
Terminal duct lobular units (TDLUs) are the predominant anatomical structures where breast cancers originate. Having lesser
degrees of age-related TDLU involution, measured as higher TDLUs counts or more epithelial TDLU substructures (acini), is
related to increased breast cancer risk among women with benign breast disease (BBD). We evaluated whether a recently
developed polygenic risk score (PRS) based on 313-common variants for breast cancer prediction is related to TDLU involution in
the background, normal breast tissue, as this could provide mechanistic clues on the genetic predisposition to breast cancer.
Among 1398 women without breast cancer, higher values of the PRS were significantly associated with higher TDLU counts
(P= 0.004), but not with acini counts (P= 0.808), in histologically normal tissue samples from donors and diagnostic BBD
biopsies. Mediation analysis indicated that TDLU counts may explain a modest proportion (≤10%) of the association of the
313-variant PRS with breast cancer risk. These findings suggest that TDLU involution might be an intermediate step in the
association between common genetic variation and breast cancer risk.
npj Breast Cancer            (2020) 6:41 ; https://doi.org/10.1038/s41523-020-00184-7
INTRODUCTION
Terminal duct lobular units (TDLUs) are the milk-producing
structures of the breast and the predominant anatomical
structures from which breast cancers originate1. Higher number
of TDLUs and higher number of acini (TDLU epithelial substruc-
tures) indicate lesser TDLU involution. Among benign breast
disease (BBD) patients, having reduced levels of TDLU involution is
associated with increased risk of subsequent breast cancer2,3.
Measures of TDLU involution are thought to reflect a global
process occurring throughout the breast2,4,5. Two studies from
European and Asian populations have also found greater TDLU
involution surrounding ER-positive compared with triple negative
breast cancers, primarily for acini measures6,7. While several
hormonal and lifestyle breast cancer risk factors are known to
affect TDLU involution8, how genetic risk factors relate to TDLU
involution is not well understood.
We previously examined whether 62 established breast cancer
susceptibility loci were associated with TDLU involution and found
limited evidence for an association9. Recently, a polygenic risk
score (PRS) for the prediction of breast cancer has been derived
using 313 common variants from the largest available interna-
tional genome-wide association dataset10. Any observed relation-
ships between the 313-variant PRS and TDLU involution may
provide mechanistic clues on the genetic predisposition to breast
cancer. ER-specific PRS have also been recently developed10.
Investigating whether ER-specific PRS are related to measures of
TDLU involution could inform whether lobular involution shows
differential relationships for genetic susceptibility predisposition
to breast cancer subtypes.
Here, we assessed the relation between the 313-variant breast
cancer PRS and TDLU involution in 1,398 women with
histologically normal donated tissues in the Susan G. Komen
Tissue Bank (KTB) at the Indiana University Simon Cancer Center
(n= 1,089)11 and in the background, normal tissue of biopsies
among participants diagnosed with BBD in the NCI Breast
Radiology Evaluation and Study of Tissues (BREAST) Stamp
Project (n= 309)12.
RESULTS
Patients characteristics
Characteristics of the participants are shown in Table 1. The
majority of the women were premenopausal (76%), parous (58%),
and 22% had a family history of breast cancer in a first degree
relative. Approximately 68% of the women had TDLUs observed,
with a median of 8.5 TDLUs/100 mm2 and 12 acini/TDLU. Age-
related TDLU involution metrics were similar in the KTB and the
BREAST Stamp studies.
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Association between the polygenic risk score for the prediction of
breast cancer and TDLU involution
Greater values of the PRS were statistically significantly associated
with higher TDLU counts (P= 0.004; Table 2). Specifically, women
in the top 25th percentile of polygenic risk had 33% increased
odds (95% CI: 1.06–1.65) of having greater TDLU counts compared
with women in the bottom 25th percentile. Results were similar,
although attenuated, after adjusting for the visually assessed
proportion of fibroglandular (nonfatty) tissue. The PRS was not
associated with acini counts/TDLU (P= 0.808). With respect to the
313 loci that formed the PRS, we found limited evidence for their
individual associations with TDLU involution measures (Supple-
mental Data 1). Analyses stratified by study population suggested
a stronger association in the tissue donors (KTB) compared to
those diagnosed with BBD (BREAST Stamp) (data not shown). ER-
positive and ER-negative PRS were both positively associated with
TDLU count (P= 0.005 for ER-positive and negative) but not with
acini count/TDLU (P= 0.861 and P= 0.715, respectively).
Mediation analysis
Mediation analysis was used to estimate the percent of the
association between the PRS and breast cancer risk that might be
explained by TDLU count (Fig. 1, Table 3). Ideally such an analysis
would be conducted in a study where the PRS, TDLU measures,
and breast cancer risk are all available. However, no study, to our
knowledge, has all three measures. Therefore, we developed a
novel approach where we used information from different sources
Table 1. Descriptive statistics of TDLU involution measures.
Characteristic Overall
(N= 1398)
Komen
Tissue Bank
(N= 1089)
BREAST Stamp
Project
(N= 309)
Age (years), n (%)
<30 318 (22.7) 318 (29.2) 0
30–39 234 (16.7) 234 (21.5) 0
40–49 431 (30.8) 274 (25.2) 157 (50.8)
50–59 301 (21.5) 186 (17.1) 115 (37.2)
≥60 114 (8.2) 77 (7.1) 37 (12.0)
Menopausal status, n (%)
Premenopausal 1,053 (76.4) 847 (79.2) 206 (66.7)
Postmenopausal 325 (23.6) 222 (20.8) 103 (33.3)
Parity, n (%)
Nulliparous 581 (41.6) 507 (46.6) 74 (23.9)
Parous 817 (58.4) 582 (53.4) 235 (76.1)
Family history, n (%)
No 1,081 (77.6) 853 (78.3) 228 (75.0)
Yes 312 (22.4) 236 (21.7) 76 (25.0)
Observed TDLUs, n (%)
No 455 (32.5) 369 (33.9) 86 (27.8)
Yes 943 (67.5) 720 (66.1) 223 (72.2)
TDLU count, median (IQR) 3 (0–11) 3 (0–11) 4 (0–14)
TDLU/(100 mm2),
median (IQR)
8.5 (0.0–31.0) 8.4 (0.0–31.8) 9.7 (0.0–26.7)
Median acini count per TDLU,
median (IQR)
12 (7–18.5) 12 (7–19) 11 (7.1–16.5)
Median acini count per TDLU
(including women with 0
TDLUs), median (IQR)
7 (0–14.5) 7 (0–15) 8 (0–13.5)
(TDLU counts per unit area) *
(acini count/TDLU), median
(IQR)
2.4 (0.8–6.4) 2.5 (0.9–7.3) 2.1 (0.6–4.7)
(TDLU count per unit area) *
(acini count/TDLU) (including
women with 0 TDLUs),
median (IQR)
0.8 (0–4.2) 0.8 (0–4.2) 0.9 (0–3.2)
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to estimate the percent explained. The relationship between the
PRS and breast cancer risk was obtained from the Breast Cancer
Association Consortium10; the estimates of the association
between TDLU counts (continuous) and breast cancer risk were
based on previous results from the Mayo Benign Breast Disease
Cohort13; and the present analysis provided the relationship
between the PRS and TDLU counts. Using this approach, we
estimated that ~4 to 7.4% of the relationship between the PRS
and breast cancer risk would be explained by TDLU counts, if the
odds ratio for the association between TDLU counts and breast
cancer risk was between 1.25 and 1.45 based on previous results
from the Mayo Benign Breast Disease Cohort.
DISCUSSION
In this study, we assessed the relation between the 313-variant
breast cancer PRS and measures of TDLU involution and found
that higher values of the PRS were significantly associated with
higher TDLU counts in histologically normal/benign breast
biopsies. Although individual single nucleotide polymorphisms
(SNPs) in the PRS have been associated with some breast cancer
risk factors (e.g., mammographic breast density14), TDLU involu-
tion is the first breast cancer risk factor found to be significantly
associated with the 313-variant PRS. Lack of TDLU involution and
elevated mammographic breast density are positively correlated
histologic and radiologic measures, respectively, of breast tissue
composition that are thought to provide independent information
about breast cancer risk in women with BBD15. Mammographic
density was not readily available in the KTB participants, and
therefore, we did not have enough statistical power to evaluate
the relationship between the 313-PRS and mammographic density
in our study. If future studies identify a relation of the 313-PRS
with mammographic density, then one could investigate inter-
relationships between the PRS, TDLU involution and mammo-
graphic density in relationship to breast cancer risk.
Our result relating the 313-PRS with TDLU counts corroborates
previous findings showing that family history of breast cancer is
associated with increased TDLU counts8. Similarly, the lack of
observed association between the PRS and acini counts/TDLU is
consistent with studies that did not find associations with family
Fig. 1 Relationship between the 313-varieant breast cancer polygenic risk score (PRS), terminal duct lobular unit (TDLU) measures and
risk of breast cancer. Estimated percent of the association between the 313-variant breast cancer polygenic risk score (PRS) and breast cancer
(BC) risk explained by terminal duct lobular unit (TDLU) counts.
Table 3. Percent of the association between the 313-variant breast cancer polygenic risk score (PRS) and breast cancer risk explained by TDLU
counts.
PRS Breast
cancer ORa,b
RRa (95% CI) P value % explained by TDLU
counts and 95% CI if
ORTDLU-BC= 1.25
c
% explained by TDLU
counts and 95% CI if
ORTDLU-BC= 1.35
c
% explained by TDLU
counts and 95% CI if
ORTDLU-BC= 1.45
c
Overall 1.61 1.12 (1.04, 1.20) 0.004 3.97 (1.94, 5.25) 5.75 (2.74, 8.09) 7.41 (3.48, 10.78)
ER+ 1.68 1.11 (1.03, 1.20) 0.005 3.47 (1.63, 4.54) 5.05 (2.36, 7.09) 6.52 (2.92, 9.46)
ER− 1.45 1.11 (1.03, 1.20) 0.005 5.28 (2.40, 7.48) 7.49 (3.41, 11.04) 9.54 (4.10, 14.40)
aOR and RR per 1 standard deviation change in the PRS.
bFrom the Breast Cancer Association Consortium (Mavaddat et al.8).
cORTDLU-BC are continuous TDLU-breast cancer risk estimates based on data presented in Figueroa et al.
11.
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history8, suggesting that there is not a strong heritable
component for the acinar TDLU substructures/size of TDLUs,
which may instead be influenced by hormonal/environmental
factors (e.g. menopausal hormone use).
Strengths of this study include the well-characterized epide-
miologic and genetic data for study participants with standar-
dized, reproducible measures of lobular involution in non-
malignant breast tissues. We also applied an innovative analytical
approach to estimate the percent of the association between PRS
and breast cancer risk potentially explained by TDLU counts. A
limitation of the current study is the lack of replication of our
findings. Our study is based on observational assessment of TDLU
involution. Although we have demonstrated strong within- and
between-rater reliability for these TDLU metrics5,8, computational
pathology approaches may offer future opportunities to advance
etiologic studies examining complex relationships between
genetic susceptibility, breast tissue composition, and breast cancer
risk. In addition, we focused our assessment of involution in the
background normal tissue, excluding any observed BBD lobules.
Even so, prior work suggests that TDLU involution in histologically
normal breast tissue may reflect a global process occurring
throughout the breast2,4,5. Finally, despite doubling the sample
size from our previous analysis9, additional samples may be
required to detect associations between individual genetic
variants and TDLU metrics.
In conclusion, we observed a statistically significant association
between a recently developed 313-variant PRS for the prediction
of breast cancer and TDLU counts, suggesting that TDLU
involution may mediate relationships underlying common genetic
susceptibility and breast cancer risk. Future studies may further
investigate the use of the PRS for the prediction of TDLU
involution, with potential applications in studies that lack
measures of lobular involution.
METHODS
Study population and samples
The study population has been previously described9. Briefly, the KTB is an
annotated biobank, which has recruited healthy women who provided
demographic, lifestyle, and cancer-related information via self-
administered questionnaire, blood samples and normal breast tissues.
Up to four breast tissue cores were obtained from the upper outer
quadrant of the breast using a standardized technique with a 10-gauge
vacuum-assisted biopsy. One sample was formalin-fixed and paraffin-
embedded and stained with hematoxylin and eosin (H&E). Whole blood
samples were collected using Vacuette® EDTA tubes. For this study, a 50 µl
aliquot of samples were reconstituted at the Cancer Genomics Research
laboratory (Leidos Biomedical Research, Inc., Frederick, MD) for genotyp-
ing. Details of the KTB have been described elsewhere (http://
komentissuebank.iu.edu/)11. The current analysis was restricted to 1507
participants recruited from January 10, 2009 through September 14, 2012,
aged 18–91 years, that were eligible for genotyping. Informed consent was
obtained from all participants to use of their specimens and questionnaire
data for research. Approval for this study was obtained from the Indiana
University Institutional Review Board (IRB) and the National Institutes of
Health Office of Human Subjects Research (NIH OHSR #4508).
The NCI BREAST Stamp Project is a cross-sectional study of mammo-
graphic density conducted among women, aged 40–65 years, who were
referred for diagnostic image-guided breast biopsy from 2007 through
2010 at the University of Vermont College of Medicine and University of
Vermont Medical Center. Demographic, lifestyle, and breast cancer risk
factor information were collected via a self-administered questionnaire and
a supplementary telephone interview. Participants underwent clinically-
indicated breast biopsies, which were formalin-fixed paraffin-embedded
blocks and H&E stained. Whole blood samples and mouthwash samples
were collected as previously described16. Blood and mouthwash samples
were processed at the University of Vermont General Clinical Research
Center. Leukocyte DNA was extracted from blood clots using phenol
chloroform, and DNA was isolated from buccal cells using Gentra Puregene
Buccal Cell Kits (Qiagen). The current analysis was restricted to 450 women
who had eligible samples for genotyping. All women provided written
informed consent and the study was approved by the IRBs at the
University of Vermont and the NCI.
TDLU involution assessment
H&E slides were scanned for image analysis on Digital Image Hub software
(SlidePath/Leica, Dublin, Ireland). The total tissue area (mm2) on the slides
was outlined using the lasso tool in Digital Image Hub and measured. The
study pathologist measured the number of TDLUs (“TDLU count”). Acini
count per TDLU was quantified using the TDLU analyzer software17,18 as
previously described9. A high intra-observer agreement (Spearman’s r >
0.90) for the TDLU measures was previously reported5,8.
OncoArray genotyping
DNA samples from 1957 women in the two studies (1507 from the KTB and
450 BREAST Stamp project) and 23 quality control samples were
genotyped on the Illumina OncoArray chip19 at the Cancer Genomics
Research laboratory (Frederick, MD, USA). Genotypes were generated using
a cluster file provided by the Genetic Associations and Mechanisms in
Oncology Consortium. Details of the OncoArray SNP selection and
genotyping calling have been described elsewhere19,20. Briefly, ~50% of
the SNPs for the OncoArray were selected to provide high coverage for
imputation of common variants. The other 50% of SNPs were selected
from lists supplied by investigators based on consortia decisions for
different diseases. Of the 568,712 variants selected for genotyping on the
OncoArray, 533,631 were successfully manufactured on the array (includ-
ing 778 duplicate probes). Of these 533,631 variants, 38,868 were defined
as problematic SNPs by the Consortium QC guideline, thus were excluded
from the current analyses.
We further excluded samples and SNPs based on the criteria defined by
the consortium QC guideline. Through a stepwise filtration, we excluded
SNPs and samples with a call rate <95% and samples with extreme
heterozygosity (>0.4 or <0.05) within each study. We also excluded 9
unexpected duplicates with genotype concordance rate >99%, excluded
one nonfemale subject with X chromosome heterozygosity close to zero
and 66 first-degree relatives based on identity by descent analysis. Using a
set of population informative SNPs20 and the 1000 Genome phase 3 data,
we identified 98 subjects of non-European descent whom we excluded
from the analyses.
After genotyping, subjects were further excluded if they had a personal
history of in situ or invasive breast cancer, has missing tissue area,
pregnant at the time of blood draw, were previous donors (in the KTB),
and/or currently taking hormone therapy, leaving an analytic population of
1398 women.
Imputation
All samples were imputed using the October 2014 (version 3) release of the
1000 Genomes Project dataset as the reference panel and using a two-
stage imputation approach using SHAPEIT221 and IMPUTE22 version 2, as in
Michailidou et al.23, run on the NIH High-Performance Computing Biowulf
cluster computing (http://hpc.nih.gov). The imputation was done in 5-MB
around intervals around each of the 313 loci in the PRS10. Imputation
quality as assessed by IMPUTE version 2 quality score was >0.80 and r2 >
0.3 for all loci.
Statistical analysis
Analyses were conducted combining data from the KTB study and BREAST
Stamp Project. The PRS for overall and ER-specific disease was computed
using the 313 loci as described in Mavaddat et al.10 and the log of effects
sizes as weights. We standardized the PRS to have units of standard
deviation (SD). With respect to the subtype-specific PRS, we used the
weights from the hybrid method in Mavaddat et al., as this method was
found to have the best performance.
Similar to our previous analyses9, we used Poisson regression models
with robust variance to compute per-SD relative risks and 95%
confidence intervals for the association of TDLU measures (i.e., TDLU
count and acini count per TDLU) with the PRS. The PRS was modeled as a
continuous variable and as a categorical variable based on quartiles
computed in the entire study population. An offset variable was included
in the model to account for the tissue area on the slide. We used the
Wald test to assess whether a linear trend between the PRS and
morphometric TDLU measures was present. Similar analyses were used to
compute per-allele RR (Supplementary Tables 1–2). We also fitted linear
C. Bodelon et al.
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regression models to confirm that the associations were not driven by
the Poisson model assumptions, similar to our previous analysis9, and
results were similar. All multivariable models were adjusted for study
population (KTB or BREAST Stamp Project) and age. Sensitivity analysis
were also carried out by adjusting for family history and visually assessed
proportion of fibroglandular tissue. No significant differences were
observed. We also conducted stratified analyses by study and by family
history (data not shown).
The estimation of the mediating effect was done using the procedure
described by Imai et al.24 and the 95% CI were obtained by the bootstrap
procedure with 10,000 resamples. For this procedure, we assumed that the
relationship between the PRS and TDLU could be described by Poisson
regression (see above) and that the parameters could be estimated using
data from this study. Furthermore, we assumed that the joint effect
between PRS and TDLU count on breast cancer could be described by
logistic regression Eq. (1):
PðBreast cancer ¼ 1jTDLU count; PRSÞ ¼ expðβ0 þ β ´ TDLU count
þγ ´ PRSÞ=ð1þ expðβ0 þ β ´ TDLU count þ γ ´ PRSÞÞ;
(1)
with parameters estimated so that the three marginal relationships were
appropriately constrained (i.e. P(Breast cancer= 1 | PRS) agreed with
Mavaddat et al.10, P(Brest cancer= 1 | TDLU count) agreed with the
assumed value from Figueroa et al.13, and f(TDLU | PRS) agreed with results
from our study). The constrained model was fit using approaches recently
developed by Chatterjee et al.25.
All statistical tests were two-sided and P values < 0.05 were considered
statistically significant. Analyses were conducted using R 3.5.2 on a Mac
platform.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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signed by the patients did not include public data sharing. To request these data,
contact Dr. Gretchen Gierach (gierachg@mail.nih.gov). However, the Susan G. Komen
Tissue Bank (KTB) data are available through the Susan G. Komen Tissue Bank (KTB)’s
virtual repository (http://virtualtissuebank.iu.edu) and the phenotype and polygenic
risk scores are available from the dbGaP repository under the following accession ID:
https://identifiers.org/dbgap:phs002062.v1.p127.
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